Examkin

Soru

Zorluk: Çok zorPharmacokinetic and Pharmacodynamic Principles

A 5252-year-old woman presents to the clinic with progressive ataxia, horizontal nystagmus, and confusion. She has a history of focal impaired awareness seizures that have been well-controlled for three years on a stable maintenance dose of phenytoin. Two weeks ago, valproic acid was added to her regimen by a different provider for worsening mood lability. Laboratory studies reveal a normal comprehensive metabolic panel and a serum albumin of 4.24.2 g/dL. Her total serum phenytoin concentration is 1414 mcg/mL (reference range: 1010-2020 mcg/mL). Suspecting toxicity despite the reassuring total level, the physician orders a free serum phenytoin level, which returns markedly elevated at 3.23.2 mcg/mL (reference range: 1.01.0-2.02.0 mcg/mL). Which of the following pharmacokinetic mechanisms best explains the discordance between the total and free serum drug concentrations in this patient?

  1. Competitive displacement from plasma proteins combined with inhibition of hepatic oxidative metabolismCevap
  2. B
    Transition to zero-order elimination kinetics causing disproportionate accumulation of the unbound drug fraction
  3. C
    Decreased renal clearance of the unbound drug secondary to competition for proximal tubular secretion
  4. D
    Synergistic pharmacodynamic enhancement at voltage-gated sodium channels leading to clinical toxicity
  5. E
    Displacement of the primary drug from peripheral tissue binding sites leading to a decreased volume of distribution

Cevap

Competitive displacement from plasma proteins combined with inhibition of hepatic oxidative metabolism
The correct answer accurately synthesizes the dual interaction between valproic acid and phenytoin. Phenytoin is highly protein-bound (approximately 90%90\% to albumin) and is metabolized by the hepatic cytochrome P450 system (primarily CYP2C9). Valproic acid interacts with phenytoin via two distinct pharmacokinetic mechanisms. First, it competitively displaces phenytoin from albumin binding sites, which immediately increases the free (unbound) fraction of phenytoin. If this were the only interaction, the increased free fraction would temporarily increase the amount of drug available for hepatic clearance, ultimately leading to a lower total phenytoin concentration but a normalized free concentration (assuming constant dosing). However, valproic acid also acts as an inhibitor of CYP2C9. This secondary metabolic inhibition prevents the clearance of the displaced free phenytoin. The synthesis of these two mechanisms results in a laboratory profile where the total phenytoin concentration appears deceptively 'normal', while the biologically active free fraction accumulates to toxic levels, precipitating clinical symptoms such as nystagmus and ataxia.

Adım Adım Çözüm

1
Identify the clinical presentation and analyze the laboratory discordance.
The patient exhibits classic signs of phenytoin toxicity (ataxia, nystagmus) and has an elevated free phenytoin level (3.23.2 mcg/mL), despite a perfectly normal total phenytoin level (1414 mcg/mL).
Establishing the specific pharmacokinetic abnormality is required to deduce the underlying molecular drug-drug interaction.
2
Analyze the mechanism of the newly added medication (valproic acid) on protein binding.
Valproic acid is highly protein-bound and competitively displaces phenytoin from intravascular albumin binding sites.
This displacement causes an immediate increase in the free (biologically active) fraction of phenytoin, explaining why the free level is elevated relative to the total.
3
Analyze the mechanism of valproic acid on hepatic metabolism.
Valproic acid acts as an inhibitor of cytochrome P450 enzymes, particularly CYP2C9, which is the primary enzyme responsible for metabolizing phenytoin.
If displacement occurred alone, the liver would clear the extra free drug, eventually lowering the total level while normalizing the free level. Inhibition of CYP2C9 prevents this clearance.
4
Synthesize the dual interaction to explain the static total level with a toxic free level.
The combination of protein displacement (increasing the unbound fraction) and metabolic inhibition (preventing the clearance of that unbound fraction) results in a falsely reassuring normal total level that masks a toxic accumulation of active free drug.
This dual synthesis perfectly maps to the correct mechanism of interaction.

Anahtar Kavram

Valproic acid interacts with phenytoin via a dual pharmacokinetic mechanism: competitive displacement from plasma albumin (increasing the free fraction) and concurrent inhibition of CYP2C9 metabolism (preventing clearance of the displaced free drug). This leads to clinical toxicity despite 'normal' total serum drug levels.
Bu soruyu puanla

Konular

Pharmacokinetic and Pharmacodynamic Principles

Bu konudan daha fazla soru